Target intelligence / Profile preview

Chloride channel protein skeletal muscle (CLC-1) (CLC-1)

Target
CLC-1
Molecular classification
Ion channel, Voltage-gated chloride channel, CLC family
01

Overview

Chloride channel protein skeletal muscle, commonly known as CLC-1, is a voltage-gated chloride channel encoded by the CLCN1 gene and is primarily localized in the sarcolemma of skeletal muscle fibers (UniProt, P35523). It is responsible for the majority of the resting membrane conductance in these cells, which is vital for stabilizing the resting membrane potential and ensuring the rapid repolarization of the membrane after an action potential (PubMed, 30291323). By controlling the electrical excitability of the muscle, CLC-1 prevents the occurrence of spontaneous or repetitive firing that would otherwise lead to sustained muscle contraction. Mutations in the CLCN1 gene that result in a loss of function cause myotonia congenita, a genetic disorder characterized by delayed muscle relaxation and stiffness (StatPearls, NBK459217). While CLC-1 is a primary therapeutic target for treating myotonia, current pharmacological approaches often involve the use of sodium channel blockers like mexiletine to indirectly compensate for the loss of chloride conductance by reducing overall membrane excitability (PubMed, 29114044). Research continues into the development of direct CLC-1 activators as a more specific treatment strategy for myotonic disorders (NCBI, PMC5839311).

Other names
CLCN1Chloride channel 1CIC-1Skeletal muscle chloride channel
02

Mechanism of action

Stabilization of the skeletal muscle membrane potential by modulating chloride ion conductance to prevent repetitive firing of action potentials (PubMed, 30291323).

03

Biological functions

Regulation of resting membrane potentialSkeletal muscle contractionMembrane repolarizationIon transport
04

Disease associations

Myotonia congenitaBecker diseaseThomsen disease
05

Safety considerations

Cardiac arrhythmias due to non-selective sodium channel blockadeMuscle weaknessPotential for drug-drug interactions
06

Interacting drugs

Mexiletine

4 more in the full profile.

07

Biomarkers

CLCN1 gene mutationsMyotonic discharges on electromyography (EMG)Warm-up phenomenon clinical assessment

Beyond the preview

Go deeper on Chloride channel protein skeletal muscle (CLC-1) (CLC-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chloride channel protein skeletal muscle (CLC-1) (CLC-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call